INTERVIEW: Acquired assets key to Shire's 'entrepreneurial' approach to regen medicine
This article was originally published in Scrip
Executive Summary
The evolution of Shire's entrepreneurial regenerative medicine business continues with the appointment of Jeff Jonas as president of the division, which has been headquartered in San Diego, US since the $750 million acquisition of Advanced BioHealing and its bio-engineered skin substitute for diabetic foot ulcers Dermagraft in 2011 (scripintelligence.com, 18 May 2011).
You may also be interested in...
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.